SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs DefenCath could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and sales. Traders dispute how conclusive DaVitas estimate is, pointing to CMSs finalized payment rate and arguing the outlook depends on quarterly calculations and DefenCath uptake.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing RRP treatment has put Precigens PAPZIMEOS under scrutiny, with traders debating whether the new option will erode its market position. Some fear stronger competition, while others point to Precigens first-mover and full-approval advantages and question Inovios ability to commercialize its drug.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by Eylea HD and Dupixent-related collaboration revenue, are driving a sharp breakout to multiyear highs. Traders are broadly bullish on the results and follow-through, while some question whether the gains will hold.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,942,077.7905448. The last known price of Zcash is 1,263.32437248 USD and is up 2.82 over the last 24 hours. It is currently trading on 668 active market(s) with $1,115,981,976.30 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rebound and resilience amid broader crypto weakness and Binance hack fears have traders highlighting its privacy features and speculating about a safe-haven shift into ZEC; some also point to the upcoming NU7 upgrade. Others view the rally as overextended and expect further declines.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is drawing attention after Brazil approved its Valaris merger, which traders see as a step toward closing the deal, alongside recent offshore contract wins and higher day-rate expectations. Bulls anticipate improved scale and a potential short squeeze, while skeptics point to merger-related dilution, debt and the upcoming earnings report.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly results beat expectations, with record refining performance benefiting from tight diesel supplies amid geopolitical disruptions. Traders are broadly positive on the refining-led strength and shareholder returns, while some question whether the unusually strong margins can last.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

FLYs sharp decline is being discussed alongside weakness across the broader market and space stocks, with some traders citing inflation and interest-rate concerns. Others point to uncertainty over Alpha launch timing and execution, while bulls argue the selloff is sector-driven and note a lack of clear negative company news.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report and higher full-year revenue outlook, powered by demand for Mounjaro and Zepbound, have fueled LLYs rally and record highs. Traders are largely positive and cite analyst upgrades, while some question the valuation and point to trimmed profit guidance tied to acquisition-related research charges.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to a fresh 52-week high ahead of an expected quarterly report has traders focused on BRIUMVI growth and whether results can justify the run; some expect an earnings-driven move, while others warn the stock may be priced for a beat. Buyout speculation and possible short covering are also fueling bullish chatter, but no deal is confirmed and the earnings timing remains uncertain.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharply weaker quarterly outlook, driven by soft PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are split between calling the decline an overreaction and buying the dip, and warning that execution problems and continued weakness could bring further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?

Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.

Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note

Doximity (DOCS) closed the most recent trading day at $33.63, moving 1.81% from the previous trading session.

What's Next for Doximity, Inc. Shareholders After 23% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

What's Next for Doximity, Inc. Shareholders After 23% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline What's Next for Doximity, Inc. Shareholders After 23% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class...

DOCS DEADLINE: SueWallSt Reminds Doximity, Inc. Investors of Upcoming Securities Class Action Deadline

DOCS DEADLINE: SueWallSt Reminds Doximity, Inc. Investors of Upcoming Securities Class Action Deadline DOCS DEADLINE: SueWallSt Reminds Doximity, Inc. Investors of Upcoming Securities Class Action DeadlinePR NewswireNEW YORK, Oct. 29, 2026 Doximity's CEO and former CFO are named as alleged...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming Deadlines - DOCS

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming Deadlines - DOCS INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Doximity, Inc. of Class Action Lawsuit and Upcoming...

Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors

Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has launched DoseCheck, a free additional safety layer in Doximity Ask that instantly checks every AI-generated medication dosing claim against a structured drug database to reduce treatment errors and...

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & KorsinskyPR NewswireNEW YORK, Oct. 28, 2026 Wall Street...

What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Doximity, Inc.'s 23% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action...

What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Should Doximity, Inc. Investors Know After 23% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action...

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit

DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 26, 2026 NEW YORK, Oct. 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds...

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity Inc - Ordinary Shares - Class A

DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>CEO Jeff Tangney attributed Doximity’s performance over Anthropic to proprietary medical data and physician oversight.</li><li>Canaccord and BMO Capital raised their price targets on Doximity, citing growing demand for the company's AI products.</li><li>Canaccord forecast that AI revenue would become a meaningful growth driver in the third quarter.</li></ul>Shares of Doximity (DOCS) surged as much as over 200% in pre-market trade on Friday before paring most of the gains despite an earnings miss after CEO Jeff Tangney touted the company’s growing artificial intelligence capabilities and said that its clinical AI outperformed Anthropic's latest model in physician-focused testing.&nbsp;During the earnings call, Chief Executive Jeff Tangney said Doximity's clinical AI recorded a 4.8% error rate, compared with 13.6% for what he called Anthropic's “best model”, Fable 5.Canaccord also raised its price target on DOCS stock to $36 from $30 and kept a ‘Buy’ rating on the shares, citing growing demand for Doximity's AI products, especially from pharmaceutical companies. Meanwhile, BMO Capital raised its price target to $30 from $20 and kept a ‘Market Perform’ rating on the shares.&nbsp;DOCS stock more than tripled at one point in pre-market trading before the rally cooled to about 100%, putting the shares on track to hit a six-month high. The stock was among the top trending tickers on Stocktwits, and on track to hit highs not seen since January.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/DOCS_2026_08_07_07_30_17_c573acda34.png" alt="DOCS_2026-08-07_07-30-17.png" width="2643" height="1588"><figcaption>DOCS stock’s performance year-to-date. | Source: TradingView</figcaption></figure>If the gains hold above 40%, the rally would mark the biggest single-day gain in the stock's history, surpassing the previous record of 38.74% set in August 2024.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260807_072949232_ff7ee6d5f9.png" alt="koyfin_20260807_072949232.png" width="2400" height="1240"><figcaption>DOCS stock’s historical single-day gains. | Source: Koyfin</figcaption></figure><h2 class="st-heading-2">Doximity Says Its AI Outperformed Anthropic</h2>Tangney said Doximity’s performance advantage over Anthropic stemmed from two key differentiators. The first is a built-in, expert-verified drug reference system designed to improve dosing accuracy and drug interaction checks. The other is a network of more than 12,000 physician "PeerCheck" editors who continuously review and refine the platform's AI-generated responses."We're proving you can still post best-in-class software margins while investing heavily in clinical AI," Tangney said. "We're leaning in because we see a once-in-a-generation opportunity to build the new AI age of medicine."He added that AI represents "the next chapter" in Doximity's growth strategy, building on its position as a digital platform for physicians.<h2 class="st-heading-2">Canaccord Sees AI Becoming A Major Growth Driver</h2>The brokerage said AI revenue has yet to materially contribute to Doximity's financial results but is already generating meaningful customer interest.&nbsp;Analysts pointed to growing demand from pharmaceutical companies for Doximity's AI tools, particularly search marketing capabilities within its "Ask" platform, which they said is driving engagement with clients.Canaccord expects meaningful AI monetization to begin in the third quarter, with the segment becoming an increasingly important contributor to the company's long-term growth.BMO Capital echoed the view, stating AI Search traction and increased AI utilization support long-term monetization. However, the firm added that near-term margin pressure from higher compute costs may weigh on the balance sheet.<h2 class="st-heading-2">How Is Retail Feeling About DOCS Stock?</h2>On Stocktwits, retail sentiment around DOCS stock improved to ‘extremely bullish’ from ‘bullish’ over the past day, while chatter rose to ‘extremely high’ from ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_08_07_070424_1_03bfe0a28d.png" alt="Screenshot 2026-08-07 070424 (1).png" width="1274" height="684"><figcaption>DOCS stock retail sentiment on August 7 as of 7:45 a.m. ET | Source: Stocktwits</figcaption></figure>Many retail traders on the platform warned that the rally in DOCS might be a short squeeze in the making.<stembedurl>https://www.stocktwits.com/Iorgi/message/661226224</stembedurl><stembedurl>https://www.stocktwits.com/AsymmetricUpsideEnjoyer/message/661231790</stembedurl>Not accounting for the pre-market rally, DOCS stock has dropped more than 50% this year and nearly 65% in the last 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soun-stock-hits-2-month-high-biggest-single-day-gain-price-target-cuts/cZoBcXZRJJE">SOUN Stock Hits 2-Month High, Rallying Toward Biggest Gain in 3 Months Despite Analyst Target Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Doximity, Inc. logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.

DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets

CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.


Doximity Inc

iShares U.S. Healthcare Providers ETF

iShares Core S&P Mid-Cap ETF

Vanguard Health Care ETF

$DOCS

$AAOI

$CRSR

$TEAM

$DOCS, $AAOI, $CRSR, and $TEAM are all surging following their respective earnings reports. Which of these earnings declines are you most interested in buying? Vote and explain your reasoning in the comments.

Which of these earnings rallies are you most interested in buying - $DOCS, $AAOI, $CRSR, or $TEAM?

Stocktwits

Applied Optoelectronics Inc

Corsair Gaming Inc

Atlassian Corporation Plc

Which of these earnings rallies are you most interested in buying - 

Stocktwits Polls

$DOCS (Doximity, the online network for over 85% of US doctors): UpToDate content will show up inside its Ask AI tool only for clinicians at health systems that use both products, starting in the coming weeks. No financial terms given; DOCS is worth about $5.91B at $32.845 (09:52 ET, Oct 20, 2026), and Ask's AI suite is in 165+ health systems. Other side: Wolters Kluwer signed similar UpToDate deals with Microsoft and Suki, so the content isn't unique to Ask. Next: Q2 results after the close Nov 5, vs a $170M-$171M revenue guide.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DOCS Doximity Inc

Fundamentals

Latest DOCS News